Preparation and evaluation of sustained release formulation of PLGA using a new injection system based on ink-jet injection technology.

Controlled release Drug delivery Fine droplet drying process PLGA microspheres Spray drying Water-soluble drugs

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Mar 2023
Historique:
received: 21 11 2022
revised: 05 02 2023
accepted: 12 02 2023
pubmed: 24 2 2023
medline: 21 3 2023
entrez: 23 2 2023
Statut: ppublish

Résumé

We developed a method for the preparation of PLGA particles exhibiting long-term sustained-release of entrapped drugs. The fine droplet drying (FDD) technology using a new injection system based on ink-jet injection technology was adapted as the preparation method. PLGA microspheres containing TRITC-dextran, acetaminophen, and albumin as model drugs were prepared by the FDD technology. The resultant microspheres were uniform in size, with average particle sizes ranging from 16.3 to 33.0 μm and SPAN factors ranging from 0.49 to 0.77. The encapsulation efficiency of drugs showed high values ranging from 75 to 99 wt% of the total amount of water-soluble drug contained in the particles. In an investigation of the optimal operation conditions of the FDD technology, the dew point temperature of the dryer air stream was found to be an important factor for controlling the initial burst of the prepared particles. The TRITC-dextran-containing PLGA microspheres were confirmed to exhibit long-term sustained release for about 90 days, and the mechanism was found to be PLGA degradation rate-limiting. Based on these results, we concluded that long-term sustained-released PLGA particles can be prepared by using FDD technology under a suitable drying condition for controlling the initial burst.

Identifiants

pubmed: 36822339
pii: S0378-5173(23)00151-5
doi: 10.1016/j.ijpharm.2023.122731
pii:
doi:

Substances chimiques

Delayed-Action Preparations 0
Polylactic Acid-Polyglycolic Acid Copolymer 1SIA8062RS
Dextrans 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122731

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yuichi Sato (Y)

Laboratory of Advanced Pharmaceutical Process Engineering, Gifu Pharmaceutical University, Gifu 502-8585, Japan; RICOH Co., Ltd., Kanagawa 243-0460, Japan. Electronic address: yuuichi.su.satoh@jp.rioch.com.

Tatsuru Moritani (T)

RICOH Co., Ltd., Kanagawa 243-0460, Japan.

Ryota Inoue (R)

RICOH Co., Ltd., Kanagawa 243-0460, Japan.

Hirofumi Takeuchi (H)

Laboratory of Advanced Pharmaceutical Process Engineering, Gifu Pharmaceutical University, Gifu 502-8585, Japan.

Articles similaires

Editorial Policies Humans Ethics, Research Technology

Gender parity in African science.

Kwabena Boahen Asare, Fatima Cody Stanford
1.00
Humans Female Science Mathematics Technology
Nanoparticles Needles Polylactic Acid-Polyglycolic Acid Copolymer Polyethylene Glycols Curcumin
Fusarium Pigments, Biological Gamma Rays Chitosan Culture Media

Classifications MeSH